Market Overview

UPDATE: Deutsche Bank Initiates Buy on Achillion Pharmaceuticals

Share:
Related ACHN
Deutsche Bank Loves These Small-Cap Biotech Stocks
Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Deutsche Bank initiated its coverage on Achillion Pharmaceuticals (NASDAQ: ACHN) with a Buy rating and a price target of $12 per share.

Deutsche Bank said, "ACHN's first R&D Day is 9/27. We believe ACHN has HCV drugs that will be very competitive in a big HCV market. … We think 3102 will show easily over 3 logs of viral reduction making it very competitive relative to all classes of HCV drugs. Our focus will be on the resistance profile for 3102. We think 3102 could work in mutations where first gen NS5As (ABT&GILD) do not. We expect some color on this at R&D Day."

Achillion Pharmaceuticals closed at $8.28 on Tuesday.

Latest Ratings for ACHN

DateFirmActionFromTo
Dec 2014BairdDowngradesOutperformNeutral
Dec 2014Deutsche BankMaintainsBuy
Sep 2014UBSMaintainsBuy

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

Posted-In: Deutsche BankInitiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ACHN)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional